NeuroBo Pharmaceuticals (NASDAQ:NRBO) Trading Down 3.2%

Shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBOGet Free Report) dropped 3.2% during trading on Tuesday . The company traded as low as $3.85 and last traded at $3.93. Approximately 27,715 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 1,329,710 shares. The stock had previously closed at $4.06.

NeuroBo Pharmaceuticals Price Performance

The business’s 50 day simple moving average is $4.73 and its 200 day simple moving average is $4.01.

Institutional Trading of NeuroBo Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in NRBO. Renaissance Technologies LLC acquired a new stake in NeuroBo Pharmaceuticals in the second quarter valued at $28,000. Two Sigma Investments LP acquired a new stake in NeuroBo Pharmaceuticals in the fourth quarter valued at $47,000. Millennium Management LLC acquired a new stake in NeuroBo Pharmaceuticals in the fourth quarter valued at $33,000. Finally, Vanguard Group Inc. acquired a new stake in NeuroBo Pharmaceuticals in the third quarter valued at $33,000. Institutional investors and hedge funds own 1.37% of the company’s stock.

NeuroBo Pharmaceuticals Company Profile

(Get Free Report)

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.

Read More

Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.